HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Subcortical vascular dementia — Clinical Guidelines

Overview

Subcortical vascular dementia (SVaD) is a form of vascular dementia resulting from chronic small vessel disease, characterized by white matter lesions, lacunar infarcts, and impaired neurovascular coupling, leading to cognitive decline, particularly executive dysfunction and behavioral changes 1 5 7.

Diagnosis

MRI Findings: Presence of white matter hyperintensities (WMH), lacunes, and cerebral microhemorrhages 1 4 10.

Neuropsychological Testing: Cognitive impairment, especially in executive function and attention 8 6.

Functional Assessments: Gait disorders and apathy as relevant clinical markers 7.

Imaging Techniques: Resting-state fMRI and near-infrared spectroscopy (NIRS) for assessing functional connectivity and metabolic changes 9.

Management

Cognitive Support: Rivastigmine for executive dysfunction and behavioral symptoms; specific dosing not detailed but shown to have slight improvement 15.

Behavioral Management: Addressing apathy and gait disorders through multidisciplinary approaches 7.

Monitoring and Support: Regular cognitive assessments using tools like Montreal Cognitive Assessment (MoCA) for early detection 8.

Special Populations

Elderly: Increased vulnerability to functional decline and cognitive impairment; longitudinal monitoring essential 17.

Comorbidities: Consider impact of hypertension and hyperlipidemia on disease progression 4 5.

Key Recommendations

Utilize MRI to identify WMH, lacunes, and microhemorrhages for diagnosis and monitoring disease progression (Evidence: Moderate 1 10).

Employ neuropsychological tests, particularly MoCA, for early detection and differentiation of cognitive impairment stages (Evidence: Moderate 8).

Consider rivastigmine for symptomatic relief in executive dysfunction and behavioral symptoms, though efficacy is modest (Evidence: Weak 15).

Regularly assess functional abilities, including gait and ADL, to manage and predict decline in elderly patients (Evidence: Moderate 17).

Address comorbidities like hypertension and hyperlipidemia to potentially slow disease progression (Evidence: Expert opinion 4 5).

References

1 Huang J, Wang W, Cheng R, Liu X, Chen L, Luo T. A multi-parametric MRI study on changes in the structure, function, and connectivity of thalamic subregions and their relationship with cognitive impairment in patients with subcortical ischemic vascular disease. Brain research 2025. link 2 Sang L, Wang L, Zhang J, Qiao L, Li P, Zhang Y et al.. Progressive alteration of dynamic functional connectivity patterns in subcortical ischemic vascular cognitive impairment patients. Neurobiology of aging 2023. link 3 Kang SH, Woo SY, Kim S, Kim JP, Jang H, Koh SB et al.. Independent effects of amyloid and vascular markers on long-term functional outcomes: An 8-year longitudinal study of subcortical vascular cognitive impairment. European journal of neurology 2022. link 4 Yu D, Hennebelle M, Sahlas DJ, Ramirez J, Gao F, Masellis M et al.. Soluble Epoxide Hydrolase-Derived Linoleic Acid Oxylipins in Serum Are Associated with Periventricular White Matter Hyperintensities and Vascular Cognitive Impairment. Translational stroke research 2019. link 5 Lee ES, Yoon JH, Choi J, Andika FR, Lee T, Jeong Y. A mouse model of subcortical vascular dementia reflecting degeneration of cerebral white matter and microcirculation. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2019. link 6 Diciotti S, Orsolini S, Salvadori E, Giorgio A, Toschi N, Ciulli S et al.. Resting state fMRI regional homogeneity correlates with cognition measures in subcortical vascular cognitive impairment. Journal of the neurological sciences 2017. link 7 Moretti R, Cavressi M, Tomietto P. Gait and apathy as relevant symptoms of subcortical vascular dementia. American journal of Alzheimer's disease and other dementias 2015. link 8 Xu Q, Cao WW, Mi JH, Yu L, Lin Y, Li YS. Brief screening for mild cognitive impairment in subcortical ischemic vascular disease: a comparison study of the Montreal Cognitive Assessment with the Mini-Mental State Examination. European neurology 2014. link 9 Tak S, Yoon SJ, Jang J, Yoo K, Jeong Y, Ye JC. Quantitative analysis of hemodynamic and metabolic changes in subcortical vascular dementia using simultaneous near-infrared spectroscopy and fMRI measurements. NeuroImage 2011. link 10 Viswanathan A, Godin O, Jouvent E, O'Sullivan M, Gschwendtner A, Peters N et al.. Impact of MRI markers in subcortical vascular dementia: a multi-modal analysis in CADASIL. Neurobiology of aging 2010. link 11 Carey CL, Kramer JH, Josephson SA, Mungas D, Reed BR, Schuff N et al.. Subcortical lacunes are associated with executive dysfunction in cognitively normal elderly. Stroke 2008. link 12 Rösler A, Ulrich C, Billino J, Sterzer P, Weidauer S, Bernhardt T et al.. Effects of arousing emotional scenes on the distribution of visuospatial attention: changes with aging and early subcortical vascular dementia. Journal of the neurological sciences 2005. link 13 Chen CP. Transcultural expression of subcortical vascular disease. Journal of the neurological sciences 2004. link 14 Reed BR, Eberling JL, Mungas D, Weiner M, Kramer JH, Jagust WJ. Effects of white matter lesions and lacunes on cortical function. Archives of neurology 2004. link 15 Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. American journal of Alzheimer's disease and other dementias 2003. link 16 Yang DW, Kim BS, Park JK, Kim SY, Kim EN, Sohn HS. Analysis of cerebral blood flow of subcortical vascular dementia with single photon emission computed tomography: adaptation of statistical parametric mapping. Journal of the neurological sciences 2002. link00291-5) 17 Bennett HP, Corbett AJ, Gaden S, Grayson DA, Kril JJ, Broe GA. Subcortical vascular disease and functional decline: a 6-year predictor study. Journal of the American Geriatrics Society 2002. link 18 Fimm B, Zahn R, Mull M, Kemeny S, Buchwald F, Block F et al.. Asymmetries of visual attention after circumscribed subcortical vascular lesions. Journal of neurology, neurosurgery, and psychiatry 2001. link 19 Mungas D, Jagust WJ, Reed BR, Kramer JH, Weiner MW, Schuff N et al.. MRI predictors of cognition in subcortical ischemic vascular disease and Alzheimer's disease. Neurology 2001. link 20 Fein G, Di Sclafani V, Tanabe J, Cardenas V, Weiner MW, Jagust WJ et al.. Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease. Neurology 2000. link 21 Yamanouchi H. Loss of white matter oligodendrocytes and astrocytes in progressive subcortical vascular encephalopathy of Binswanger type. Acta neurologica Scandinavica 1991. link 22 Yamamura T, Nishimura M, Shirabe T, Fujita M. Subcortical vascular encephalopathy in a normotensive, young adult with premature baldness and spondylitis deformans. A clinicopathological study and review of the literature. Journal of the neurological sciences 1987. link90059-1)

Subcortical vascular dementia